Track Fractyl Health, Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Fractyl Health, Inc. Common Stock GUTS · Stock Open Fractyl Health, Inc. Common Stock in new tab

0.9000 USD
EPS
-10.56
P/B
-6.43
ROE
-778.33
Beta
2.89
Target Price
23.60 USD
Fractyl Health, Inc. Common Stock logo

Fractyl Health, Inc. Common Stock

🧾 Earnings Recap – Q3 2026

Fractyl Health rose 11.3% after reporting that REMAIN-1 met its six-month co-primary endpoint, supporting the potential of Revita to help patients maintain weight loss after stopping tirzepatide. The result is encouraging, but the 12-month endpoint remains unreported and is expected in Q1 2027.

  • In REMAIN-1, participants lost an average of 18.3% of body weight on tirzepatide before stopping treatment; 308 participants were included in the modified intention-to-treat population.
  • At six months, Revita participants retained about 80% of their prior weight loss; the co-primary endpoint was met with a p-value of 0.0023.
  • Management reported that the separation from sham widened from months 1 to 6. A post hoc analysis found the best-performing patients, treated over roughly 20 centimeters or more, had less than half the weight regain of sham.
  • One in three Revita participants were weight-stable or had lost more weight six months after stopping tirzepatide, and nearly half retained at least 80% of their weight loss.
  • The company reported no device- or procedure-related serious adverse events, deaths, or unanticipated adverse device effects. The formal 12-month endpoint is expected in Q1 2027; management also said a de novo application is planned later this quarter.
📅
Loading chart...
Key Metrics
Earnings dateApril 5, 2027
EPS-10.56
Book Value-0.13
Price to Book-6.43
Debt/Equity284.50
% Insiders1.454%
Growth
Revenue Growth5.60%
Estimates
Forward P/E-0.22
Forward EPS-3.62
Target Mean Price23.60

DCF valuation

Model fair value for Fractyl Health, Inc. Common Stock (GUTS)
Result
Sign in to run the valuation for GUTS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Strong buy · mean target 23.60 USD (low 5.00, high 60.00) · as of 11 Nov 2026
Low 5.00
Mean 23.60
High 60.00
Price 0.9000
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Fractyl Health, Inc. Common Stock Logo Fractyl Health, Inc. Common Stock Analysis (GUTS)

Healthcare Official Website Stock

Is Fractyl Health, Inc. Common Stock a good investment? Fractyl Health, Inc. Common Stock (GUTS) is currently trading at 0.9000 USD. Market analysts have a consensus price target of 23.60 USD. This suggests a potential upside from current levels.

Earnings Schedule: Fractyl Health, Inc. Common Stock is expected to release its next earnings report on April 5, 2027. The market consensus estimate for Forward EPS is -3.62.

Investor FAQ

Does Fractyl Health, Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Fractyl Health, Inc. Common Stock?

Fractyl Health, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 5, 2027. The company currently has a trailing EPS of -10.56.

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Exchange Ticker
NASDAQ GUTS
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Oct. 5, 2026 1:12
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion